Dengue vaccine

Dengue Vaccine is a vaccine used to prevent Dengue fever, a mosquito-borne tropical disease caused by the dengue virus. Dengue fever is a significant cause of illness and death in the tropics and subtropics, with over 2.5 billion people at risk for the disease worldwide.

History

The development of a dengue vaccine has been a public health priority for many years. The first dengue vaccine, Dengvaxia (CYD-TDV) by Sanofi Pasteur, was first licensed in 2015 and has been introduced in the national immunization programs of several countries.

Types of Dengue Vaccines

There are several types of dengue vaccines that are in various stages of development. These include:

• Dengvaxia (CYD-TDV) by Sanofi Pasteur
• TAK-003 by Takeda Pharmaceutical Company
• TV003/TV005 by the U.S. National Institutes of Health
• DENVax by Panacea Biotec

Efficacy and Safety

The efficacy and safety of dengue vaccines are still under study. The World Health Organization (WHO) recommends the use of the Dengvaxia vaccine in individuals aged 9-45 years living in areas where dengue is endemic and who have confirmed previous dengue virus infection.

Side Effects

Like all vaccines, dengue vaccines can cause side effects, although not everybody gets them. The most common side effects are mild and include pain at the injection site, headache, and mild fever.

Future Research

Future research on dengue vaccines focuses on improving the efficacy and safety of the vaccines, as well as developing vaccines that can provide protection against all four dengue virus serotypes.

See Also

• Dengue fever
• Vaccine
• Dengue virus
• World Health Organization

References

Dengue vaccine Resources
Latest articles Most recent articles Ongoing trials	Wikipedia